Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Dexmedetomidine vs fentanyl as an add-on to bupivacaine for nerve blocks in high-risk patients undergoing above-knee amputation

Official title: The Analgesic Efficacy of Dexmedetomidine Versus Fentanyl as an Adjuvant to Bupivacaine in Ultrasound Guided Peripheral Nerve Blocks as a Solo Anesthetic Technique in High Risk Patients Undergoing Unilateral Above Knee Amputation : A Randomized Double Blinded Study

Run by Kasr El Aini Hospital · NCT07640516 · Data updated 2026-11-12

This study tests whether adding dexmedetomidine or fentanyl to bupivacaine for ultrasound-guided nerve blocks can provide better pain relief for adults with heart or lung disease undergoing above-knee amputation.

More Lower Limb Amputation Above Knee trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment64 (estimated)
SponsorKasr El Aini Hospital
Academic / other
Locations1 site (Cairo)
StatusRecruiting
StartedJuly 1, 2026
Main results expectedJanuary 1, 2027
Study endsMarch 1, 2027
Registry record updatedJuly 13, 2026
Trial IDNCT07640516 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with significant cardiac or pulmonary disease scheduled for unilateral above-knee amputation and suitable for a regional nerve block technique.

Probably not a fit

Patients without adequate block success or who experience adverse effects from the adjuvants may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study compares two adjuvants—dexmedetomidine and fentanyl—used with bupivacaine in ultrasound-guided nerve blocks that serve as the sole anesthetic technique for high-risk patients undergoing unilateral above-knee amputation. The blocks target the supra-inguinal fascia iliaca and proximal sciatic nerves to provide anesthesia and analgesia while avoiding general or spinal anesthesia. Eligible participants are adults (≥18) with ASA III–IV, documented cardiac or pulmonary disease, and scheduled AKA, with several exclusion criteria to ensure safety. Outcomes likely focus on analgesic efficacy and safety of the adjuvants in this high-risk surgical setting.

Why it matters

Potential benefit: If successful, the approach could improve pain control and reduce anesthesia-related risks for high-risk AKA patients.

How similar studies have gone: There is existing evidence comparing dexmedetomidine and fentanyl as adjuvants in regional anesthesia, but data in this specific high-risk AKA population is limited, making this approach relatively novel for this setting.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* \- Age ≥18 years
* Both sexes
* ASA III-IV
* Documented cardiac disease (e.g., EF \< 40%, NYHA II or higher)
* Documented pulmonary disease (e.g., COPD with FEV1 \< 60%)
* Scheduled for above-knee amputations

Exclusion Criteria:

* Neurological or intellectual disability
* Drug abuse
* Allergy to study drugs
* Pregnancy
* Contraindications to regional anesthesia (e.g., coagulopathy, local infection)
* Significant renal or hepatic impairment( plts \<75000 or INR \>1.5)
* Current anticoagulant therapy
* severe haemodynamically unstability at the time of block performance, defined as map \> 65 mmhg but achieved by high-dose vasopressors (e.g., norepinephrine ≥ 0.1 mcg/kg/min) after fluid ressuscitation .

Where it's running

  • KasrELainiH
    Cairo, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.